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Abstract
Background and Purpose: Cu/Zn superoxide dismutase (SOD1) is a major component of Lewy body-like hyaline inclusion
(LBHI) found in the postmortem tissue of SOD1-linked familial amyotrophic lateral sclerosis (FALS) patients. In our recent
studies, 14-3-3 proteins have been found in the ubiquitinated inclusions inside the anterior horn cells of spinal cords with
sporadic amyotrophic lateral sclerosis (ALS). To further investigate the role of 14-3-3 proteins in ALS, we performed
immunohistochemical analysis of 14-3-3 proteins and compared their distributions with those of SOD1 in FALS patients and
SOD1-overexpressing mice.
Methods: We examined the postmortem brains and the spinal cords of three FALS cases (A4V SOD1 mutant). Transgenic
mice expressing the G93A mutant human SOD1 (mutant SOD1-Tg mice), transgenic mice expressing the wild-type human
SOD1 (wild-type SOD1-Tg mice), and non-Tg wild-type mice were also subjected to the immunohistochemical analysis.
Results: In all the FALS patients, LBHIs were observed in the cytoplasm of the anterior horn cells, and these inclusions were
immunopositive intensely for pan 14-3-3, 14-3-3b, and 14-3-3c. In the mutant SOD1-Tg mice, a high degree of
immunoreactivity for misfolded SOD1 (C4F6) was observed in the cytoplasm, with an even greater degree of
immunoreactivity present in the cytoplasmic aggregates of the anterior horn cells in the lumbar spinal cord. Furthermore,
we have found increased 14-3-3b and 14-3-3c immunoreactivities in the mutant SOD1-Tg mice. Double immunofluorescent
staining showed that C4F6 and 14-3-3 proteins were partially co-localized in the spinal cord with FALS and the mutant
SOD1-Tg mice. In comparison, the wild-type SOD1-Tg and non-Tg wild-type mice showed no or faint immunoreactivity for
C4F6 and 14-3-3 proteins (pan 14-3-3, 14-3-3b, and 14-3-3c) in any neuronal compartments.
Discussion: These results suggest that 14-3-3 proteins may be associated with the formation of SOD1-containing inclusions,
in FALS patients and the mutant SOD1-Tg mice.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal, progressive
neurodegenerative disease characterized by the degeneration
of motor neurons in the motor cortex, brainstem and spinal cord.
The vast majority of ALS patients are sporadic, and approximately
5–10% of ALS cases are familial ALS (FALS) [1]. Among the
FALS patients, approximately 20% are linked to mutations in the
antioxidant enzyme Cu/Zn superoxide dismutase (SOD1) [2].
Mutant SOD1 proteins aggregate and form Lewy body-like
hyaline inclusions (LBHIs) in the anterior horn cells of the spinal
cord [3].
Transgenic mice carrying several copies of human mutant
SOD1 genes show ALS-like symptoms such as progressive motor
disturbances and neurogenic amyotrophy, and develop a pathol-
ogy resembling ALS [4]. In brief, these Tg mice demonstrate
atrophy of the motor neuronal system, vacuolar degeneration of
the motor neurons, and ubiquitinated neuronal hyaline
inclusions which contain SOD1 in their cell bodies and swollen
processes [5].
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these LBHIs contain ubiquitin [6], phosphorylated neurofilaments
[7], and a copper chaperone for superoxide dismutase [8].
The 14-3-3 proteins, a family of protein chaperones, are
abundant in the brain, comprising approximately 1% of the total
brain protein [9]. 14-3-3 proteins consist of seven different
isoforms, named with Greek letters (b, e, c, g, h, s, and f). Each
isoform forms homo- or hetero-dimers. 14-3-3 dimers can
simultaneously bind two ligands, modulate different signaling
molecules and participate in cell cycle control, cell adhesion,
neuronal plasticity as well as various intracellular signal transduc-
tion pathways [10]. 14-3-3 proteins seem to control the subcellular
localization of proteins and to function as adaptor molecules,
stimulating protein-protein interactions. The regulation of this
interaction usually involves the phosphorylation of the interacting
proteins [11].
In our recent studies, several types of 14-3-3 proteins such as 14-
3-3b, 14-3-3c, 14-3-3f, 14-3-3h, or 14-3-3e have been found in the
ubiquitinated inclusions of anterior horn cells from patients with
sporadic ALS [12]. 14-3-3 mRNA was also demonstrated to be
upregulated in the spinal cords with sporadic ALS [13].
However, the association of 14-3-3 proteins with FALS remains
unknown. In this study, to investigate the role of 14-3-3 proteins
and SOD1 in the pathogenesis of FALS, we performed
immunohistochemical staining for 14-3-3 proteins and SOD1 in
formalin-fixed, paraffin-embedded sections from patients with
FALS. Transgenic mice which overexpress mutant human SOD1,
transgenic mice which overexpress wild type human SOD1, and
non-transgenic wild-type mice were also subjected to immunohis-
tochemical analysis.
Methods
Ethics Statement
The protocols for genetic analysis and neuropathological
procedures were approved by and performed under the guidelines
of our institutional ethics committee. Informed consent was
obtained from all individuals or their guardians before the
analysis. The animal study was carried out in strict accordance
with the guidelines for animal experimentation from the Animal
Research Committee of our institution. The protocol was
approved by the Animal Research Committee, Kyoto University
(Permit Number: MedKyo10202).
Human FALS cases
We analyzed three cases of FALS (A4V SOD1 mutant). The
clinicopathological backgrounds of these FALS cases have been
previously reported [14]. These patients were members of the
American ‘‘C’’ family. The three patients were males, and their
ages at death were 39, 46 and 66 years. They were pathologically
consistent with FALS with posterior column involvement [15].
Transgenic mice expressing G93A mutant human SOD1
and wild type human SOD1
We used transgenic mice expressing the G93A mutant human
SOD1 gene (mutant SOD1-Tg mice) [B6SJL-TgN (SOD1-G93A)
1Gur] and wild-type human SOD1 gene (wild-type SOD1-Tg
mice) [B6SJL-Tg (SOD1) 2Gur/J], which were originally obtained
from the Jackson Laboratory [16]. The mutant SOD1-Tg mice
develop signs of hind limb weakness at the age of 3 to 4 months. At
the age of 5 to 6 months, they are not able to forage for food and
water and then die. The wild-type SOD1-Tg mice show no motor
symptoms [17]. We analyzed four-month-old mutant SOD1-Tg
and wild-type SOD1-Tg mice (n=4, each).
Human tissues
Human tissue blocks obtained from the different levels of spinal
cords of FALS cases were embedded in paraffin. The blocks were
sectioned with a microtome at 6 mm thickness for routine and
immunohistochemical staining. Routine histological assessment
was carried out with hematoxylin and eosin (H&E).
H&E-stained sections with LBHIs were photographed, decol-
orized with 70% ethanol and pretreated with 0.3% H2O2 in
0.1 mol/L phosphate-buffered saline (PBS) for 30 min at room
temperature to inhibit any endogenous peroxidase activity. After
washing with 0.1 mol/L PBS, these sections were blocked with
0.1 mol/L PBS plus 3% skim milk for 2 hours at room
temperature. Then, the specimens were used for immunohisto-
chemistry; this involved sequential incubation with primary
antibody, appropriate biotinylated secondary antibody (Vector
Laboratories, diluted 1:200), and avidin-biotin-peroxidase com-
plex (ABC; Vector Laboratories, 1:200) in 0.1 mol/L PBS
containing 0.3% Triton X-100 (PBST, pH 7.4). The sections
were rinsed with PBST for 15 min between each step and finally
visualized with 0.01% diaminobenzidinetetrahydrochloride and
0.005% H2O2 in 50 mmol/L Tris-HCl (pH 7.6).
Animal tissues
Mice were deeply anesthetized with sodium pentobarbital and
were perfused transcardially with 0.01 mol/L PBS and then with a
fixative containing 4% paraformaldehyde (PFA) and 0.2% picric
acid in 0.1 mol/L phosphate buffer (PB, pH 7.4). Then, the brains
and the spinal cords were removed. The tissues were post-fixed for
24 hours in 4% PFA and stored in 20% sucrose in 0.1 mol/L PB
(pH 7.4). Serial lumbar spinal sections were cut into 20 mm thick
sections on a cryostat, and immunohistochemical analysis was
performed in the same way as human tissues described above.
Table 1. Primary antibodies.
Primary antibody Company Dilution
C4F6 mouse
monoclonal
Reference [18] 1:1000
SOD1 goat polyclonal C-17 SC-8637 Santa Cruz
Biotechnology
1:1000
pan 14-3-3 mouse
monoclonal
H-8 SC-1657 Santa Cruz
Biotechnology
1:1000
14-3-3b rabbit polyclonal C-20 SC-628 Santa Cruz
Biotechnology
1:2000
14-3-3c rabbit polyclonal C-16 SC-731 Santa Cruz
Biotechnology
1:2000
14-3-3e rabbit polyclonal T-16 SC-1020 Santa Cruz
Biotechnology
1:400
14-3-3g goat polyclonal E-12 SC-17287 Santa Cruz
Biotechnology
1:400
14-3-3h rabbit polyclonal C-17 SC-732 Santa Cruz
Biotechnology
1:2000
14-3-3s goat polyclonal C-18 SC-7683 Santa Cruz
Biotechnology
1:400
14-3-3s goat polyclonal N-14 SC-7681 Santa Cruz
Biotechnology
1:400
14-3-3f rabbit polyclonal C-16 SC-1019 Santa Cruz
Biotechnology
1:2000
doi:10.1371/journal.pone.0020427.t001
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As primary antibodies, we used anti-SOD1, anti-misfolded
SOD1 (C4F6) [18], and anti- pan and isoform-specific 14-3-3
protein antibodies. The primary antibodies used were listed in
Table 1.
Double labeling immunohistochemistry
To investigate the relationship between SOD1 and 14-3-3
proteins, spinal cord sections of the FALS cases were incubated
with primary antibodies against SOD1 and pan 14-3-3, followed
by incubation with FITC- or rhodamine-labeled appropriate
secondary antibodies. For mouse tissues, anti-14-3-3 (b or c) and
C4F6-DyLight 488 antibodies were used. C4F6 was labeled with
DyLight Fluor 488 using a commercially available kit (DyLight
Microscale Antibody Labeling Kits, Thermo Scientific).
Results
14-3-3 immunoreactivity in patients with FALS
In all the three FALS cases, LBHIs were observed inside the
anterior horn cells (Figure 1A–C). All the LBHIs observed on
H&E showed strong pan 14-3-3 immunoreactivity (Figure 1D–F).
Using 14-3-3 isoform-specific antibodies, all the LBHIs detected
by H&E (Figure 2A, B) were intensely immunopositive both for
14-3-3b (Figure 2C) and 14-3-3c (Figure 2D).
Double immunofluorescent-stained sections showed that pan
14-3-3 was co-localized with SOD1 in the LBHI (Figure 3).
Figure 2. LBHIs immunopositive for 14-3-3b or 14-3-3c in FALS patients. A and B are the same sections as C and D, respectively. The
identical LBHIs observed on H&E (A, B) in the anterior horn cells are intensely immunostained with 14-3-3b (C) and 14-3-3c (D). Bar indicates 50 mm.
doi:10.1371/journal.pone.0020427.g002
Figure 1. LBHIs immunopositive for 14-3-3 proteins in FALS patients. A, B, and C are the same sections as D, E, and F, respectively. The
upper panels (A–C) are stained with H&E, and the lower panels (D–F) are immunostained with the anti-pan 14-3-3 antibody. LBHIs observed on H&E in
the anterior horn cells are intensely immunopositive for pan 14-3-3. Bar indicates 100 mm in (A, D), and 50 mm in (B, C, E, F).
doi:10.1371/journal.pone.0020427.g001
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the wild-type SOD1-Tg, and non-Tg wild-type mice
In mutant SOD1-Tg mice, C4F6 immunoreactivity was
observed in the remaining anterior horn cells with cytoplasmic
inclusions (Figure 4A). Immunoreactivity for C4F6 was restricted
to the glial cells that were morphologically consistent with
microglia in wild-type SOD1-Tg mice (Figure 4B) and absent in
non-Tg wild-type mice (Figure 4C).
14-3-3 immunoreactivity in the mutant SOD1-Tg, the
wild-type SOD1-Tg, and non-Tg wild-type mice
Pan 14-3-3, 14-3-3b and 14-3-3c immunoreactivities were
grossly different between the mutant SOD1-Tg and the wild-type
SOD1-Tg or non-Tg wild-type mice (Figure 5).
Such 14-3-3 immunoreactivities were strong in most of the
remaining anterior horn cells of the mutant SOD1-Tg mice
(Figure 5A, D, G), although they were not observed in the wild-
type SOD1-Tg (Figure 5B, E, H) or non-Tg wild-type mice
(Figure 5C, F, I).
Double immunofluorescent staining of C4F6 and 14-3-3b
or 14-3-3c in SOD1-Tg mice
As described above, the strong immunoreactivity of 14-3-3b and
14-3-3c were observed in the mutant SOD1-Tg mice but not in
the wild-type SOD1-Tg mice. Wherein, the distribution of
immunoreactivity for C4F6, 14-3-3b and 14-3-3c was analyzed.
All the three immunoreactivities were observed in the neuronal
somata of the anterior horn cells. Furthermore, double immuno-
fluorescent staining showed that both 14-3-3b and 14-3-3c were
partially co-localized with C4F6 in mutant SOD1-Tg mice
(Figure 6).
In negative immunohistochemical controls, some sections were
incubated with the primary antibody (0.2 mg/ml) preabsorbed
with an excess amount of the antigenic peptides, pan 14-3-3, 14-3-
3b and 14-3-3c (10 mg/ml). No specific immunopositive staining
was detected in these control sections.
Other 14-3-3 isoforms in the mutant SOD1-Tg mice and
the wild-type SOD1-Tg mice
Immunoreactivitiy for 14-3-3e, g, h, s, and f was observed in
the neuronal somata and processes in the spinal cord. However,
there were no remarkable differences in the distribution or
intensity of the immunoreactivities between the mutant SOD1-Tg
and wild-type SOD1-Tg mice.
Discussion
In this study, LBHIs in all FALS cases showed intense pan 14-3-
3, 14-3-3b and 14-3-3c immunoreactivities. Furthermore, the
double immunofluorescent study showed 14-3-3 proteins were co-
localized with SOD1 in LBHIs. Such distribution patterns were
quite similar to those of the mutant SOD1-Tg mice. This is the
first report that demonstrates a close relationship between 14-3-3
and SOD1 both in patients with FALS and mutant SOD1-Tg
mice.
We have previously reported the localization of 14-3-3 proteins
in the ubiquitinated intraneuronal inclusions in the anterior horn
cells from patients with sporadic ALS [12]. We also already
reported 14-3-3 immunoreactivity in the LBHIs in the anterior
horn cells from a patient with FALS, with a two-base pair deletion
in the SOD1 gene [19]; however, the co-localization of SOD1 and
14-3-3 was not assessed. Therefore the role of 14-3-3 proteins in
LBHI formation with a SOD1 mutation has remained unclear.
The co-localization of 14-3-3 and SOD1 in the LBHIs in both
FALS patients and mutant SOD1-Tg mice suggested that 14-3-3
may play an important role in the formation of SOD1-containing
LBHIs. The similar 14-3-3 positivity in the LBHI of sporadic ALS
and FALS with SOD1 mutation further suggests that 14-3-3 is
involved in the pathogenesis of ALS, irrespective of whether it is
sporadic or familial.
Among the various isoforms of 14-3-3 protein, Kaneko and
Hachiya proposed the possibility that a distinctive function of 14-
3-3f might be as a sweeper for misfolded proteins, such as
aggregates or inclusion bodies [20]. Santpere et al. suggested that
Figure 4. Neuronal inclusions immunopositive for C4F6 in mice. Strong immunoreactivity for C4F6 (A) was observed in the somatodendritic
compartment with cytoplasmic inclusions in the mutant SOD1-Tg mice. Immunoreactivity for C4F6 was restricted to glial cells morphologically
consistent with microglia in the wild-type SOD1-Tg mice (B) and absent in the non-Tg wild-type mice (C). Bar indicates 50 mm.
doi:10.1371/journal.pone.0020427.g004
Figure 3. A LBHI double-positive for 14-3-3 and SOD1 in a FALS patient. A LBHI in an anterior horn cell is immunostained for pan 14-3-3 (A,
green) and SOD1 (B, red), and the merged image is shown in C (yellow). Bar indicates 50 mm.
doi:10.1371/journal.pone.0020427.g003
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damage in Alzheimer’s disease [21], and some neurofibrillary
tangles were reported to be immunolabeled with 14-3-3b and 14-
3-3c [22]. Similarly, 14-3-3 proteins have been co-localized in
Lewy bodies [23] and in glial cytoplasmic inclusions from patients
with multiple system atrophy [24]. In our recent study, 14-3-3b
and 14-3-3c were strongly expressed in the neuronal somata and
processes of anterior horn cells in the spinal cord of mutant human
a-synuclein (A53T)-Tg mice, an animal model of Parkinson’s
disease (PD) [25]. Therefore, 14-3-3b and 14-3-3c may be the key
isoforms associated with the formation of a-synuclein- and SOD1-
containing inclusions. This raises the possibility that there might
be a common mechanism for inclusion formation at least between
ALS and PD.
An insufficient function of the molecular chaperones may be
directly involved in the loss of motor neurons in ALS [26,27].
Under non-pathological conditions, 14-3-3 proteins play impor-
tant roles in signal transduction, apoptotic cell death and cell cycle
Figure 5. Neuronal inclusions immunopositive for pan 14-3-3, 14-3-3b, and 14-3-3c in the spinal cord of SOD1-Tg mice. In mutant
SOD1-Tg mice, strong immunoreactivity for pan 14-3-3 (A), 14-3-3b (D), and 14-3-3c (G) were observed in the neuronal cytoplasm or neuronal process
of the lumbar anterior horn cells. Such immunoreactivities were not observed in the wild-type SOD1-Tg (B, E, H) or non-Tg wild-type mice (C, F, I). Bar
indicates 50 mm.
doi:10.1371/journal.pone.0020427.g005
Figure 6. Neuronal inclusions double-positive for C4F6 and 14-3-3 in the spinal cord of mutant SOD1-Tg mice. Immunofluorescence
for C4F6 (A, D, green), 14-3-3b (B, red), and 14-3-3c (E, red), double immunofluorescence for C4F6 and 14-3-3b (C, merge), and double
immunofluorescence for C4F6 and 14-3-3c (F, merge) are shown in the anterior horn cells. Bar indicates 20 mm.
doi:10.1371/journal.pone.0020427.g006
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inactivating pro-apoptotic proteins, including the mitochondrial
Bcl-2 family member BAD, apoptosis signal-regulating kinase 1
(ASK1), and the Forkhead transcription factor FKHRL1 [10].
Therefore, the sequestration of 14-3-3 may cause neuronal
dysfunction and thus contribute to cell death. Strong immunore-
activity for 14-3-3 in the LBHIs of FALS patients and in the
mutant SOD1-Tg mice suggested that 14-3-3 proteins are trapped
in the LBHIs, and this deficiency of the 14-3-3 proteins causes
motor neuronal death in patient with FALS.
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